Skip to main content
OpenTrials
Completed

NCT Number: NCT02197026

Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee Osteoarthritis

Comparison of treatment cost of knee osteoarthritis (OA) in patients treated with Synvisc® versus usual treatments as well as evaluation of safety and effectiveness of these treatments.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female outpatient aged at least 18 years
  • Patient suffering from predominant femoro-tibial knee osteoarthrosis with or without effusion. The diagnosis must be based on American College of Rheumatology (ACR) criteria. Radiological grade will be assess according to Kellgren-Lawrence scale
  • Assessment of pain on active movement (i.e. walking) (by the patient) must be at least 40 mm on a 100 mm VAS
  • Patient who received at least two courses of at least ten days within the last three months with non-steroidal antiinflammatory drugs (NSAID) and/or who are treated continuously for the last two month with slow-acting anti-osteoarthritis drugs
  • Patient's informed written consent obtained in accordance with French legislation

Exclusion criteria

  • Patient suffering from acute congestive osteoarthritis flare of the target knee (at the time of inclusion) which means that concomitantly to knee effusion at least 2 of the following criteria are present:
  • nocturnal disturbances due to knee pain
  • morning stiffness over 45 minutes
  • increase of knee pain more than 50% within the last week
  • articular reddening
  • articular heat
  • Intra-articular administration of hyaluronic acid in the target knee within the previous year
  • Intra-articular administration of hyaluronic acid in the target knee within the three previous months
  • Any other intra-articular injection in the target knee within the last 6 months
  • Any contraindication to intra-articular injections
  • Present or past history of infected target knee joint
  • Previous prosthesis knee surgery, tibial osteotomy, synovectomy or synoviorthese of the target knee
  • Arthroscopy, articular lavage, debridement, menisectomy of the target knee within the previous year
  • Planned knee surgery within the nine following month
  • Any other musculoskeletal disorders that can interfere with osteoarthritis diagnosis or the evaluation of its severity
  • Known hypersensitivity to avian products
  • Presence of lymphatic or venous stasis
  • Pregnancy or breastfeeding
  • Clinical evidence of or known severe cardiac, hepatic, renal, metabolic, haematological disease, mental disturbance
  • Participation in another clinical trial during this study or during the previous month
  • Previous participation in this trial
  • Patient who requires help concerning shopping or house keeping
  • Patient unable to comply with the protocol (e.g. patient unable to attend each trial visit or to fill the diary booklet or the quality of life questionnaire)

Treatment and study plan

Hylan G-F 20

Drug

Other names: Synvisc®

standard treatment

Drug

Standard drug treatment at the discretion of the investigator

physiotherapy

Procedure

hydrotherapy

Procedure

Primary outcomes

  1. Cost of knee OA treatment including cost of side effect related to OA treatment

    Time frame: up to 274 days

  2. Area under the curve (AUC) Lequesne index

    Time frame: Day 1, 29, 91, 182 and 274

    Index of severity

Secondary outcomes

  1. Assessment of Western Ontario and McMaster Universities (WOMAC) index by patient

    Time frame: Day 1, 91, 182 and 274

  2. Patient's assessment of pain on movement and rest on a visual analogue scale (VAS) through WOMAC question 1 and 3

    Time frame: Day 1, 91, 182 and 274

  3. Disease activity assessment by patient and investigator on a VAS

    Time frame: Day 1, 29, 91, 182 and 274

  4. Acute congestive OA flares assessed through a questionnaire

    Time frame: Day 1, 29, 91, 182 and 274

  5. Assessment of state of health of the patients with a quality of life questionnaire (SF 12)

    Time frame: Day 1, 91, 182, 274

  6. Final global assessment of efficacy by patient and investigator on a four-point verbal rating scale (VRS)

    Time frame: Day 274

  7. Final global assessment of tolerability by patient and investigator on a four-point VRS

    Time frame: Day 274

  8. Incidence and intensity of adverse events

    Time frame: up to day 274

  9. Number of withdrawals due to adverse event

    Time frame: up to day 274

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Multicentre, Open-label and Randomized Clinical Trial to Compare in Patient With Knee Osteoarthritis the Medicoeconomic Benefits as Well as Effectiveness and Safety of Synvisc® Versus Usual Treatments.

Important dates

Study start
1998
Primary completion
2000
First posted
Jul 22, 2014
Registry last updated
Jul 22, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.